Full-Time
Translational Science Lead
Confirmed live in the last 24 hours
PathAI
201-500 employees
AI-powered pathology platform for diagnostics
Mid, Senior
Remote in USA
You match the following PathAI's candidate preferences
Employers are more likely to interview you if you match these preferences:
- 0-3 years of experience in biotech, pharmaceutical, or medical device industries with a PhD, OR 3+ years of experience with a Master’s degree, OR 5+ years of experience with a Bachelor’s degree in life sciences or biomedical engineering-related disciplines.
- Advanced degree in life sciences or biomedical engineering-related disciplines required, PhD preferred.
- Ability to process quantitative datasets and broad comfort with statistics.
- Intellectual curiosity and the ability to learn quickly in a complex space.
- Strong organizational skills and experience managing project timelines.
- Responsible for the scientific and strategic development of company projects.
- Drive and uphold rigorous scientific standards, bringing consistency to the analyses you encounter and ensuring our discoveries are adequately reviewed.
- Apply cutting edge approaches towards understanding disease biology to improve precision medicine and biomarker development.
- Solve interesting problems with machine learning and data science.
- Oversee day-to-day technical developments and manage relationships with internal and external stakeholders.
- Collaborate across a range of groups - product, design, machine learning, business development, and operational teams.
- Provide product feedback and recommend new capabilities for internal and external users.
- Mentor, learn, and share knowledge with others along the way.
PathAI focuses on improving patient outcomes by using an AI-powered pathology platform. This platform enhances the accuracy of diagnoses and the effectiveness of treatments for diseases like cancer through advanced machine learning techniques. PathAI provides diagnostic tools and services to healthcare providers, research institutions, and pharmaceutical companies, generating revenue through partnerships, licensing, and service fees. What sets PathAI apart from its competitors is its commitment to solving complex healthcare problems with a diverse team and a focus on making a significant impact in the medical field. The company's goal is to ensure better patient outcomes by leveraging technology in pathology.
Company Size
201-500
Company Stage
Debt Financing
Total Funding
$251.6M
Headquarters
Boston, Massachusetts
Founded
2016
Simplify's Take
What believers are saying
- PathAI's CE mark certification enables expansion into the European diagnostic market.
- Partnerships with biobanks provide access to large datasets for AI model training.
- AI-driven tools improve diagnostic accuracy and efficiency in pathology workflows.
What critics are saying
- Emerging AI pathology startups could threaten PathAI's market share.
- Rapid AI advancements require continuous R&D investment to remain competitive.
- Ethical concerns and regulatory scrutiny may slow adoption of AI diagnostic tools.
What makes PathAI unique
- PathAI offers end-to-end automation for scalable, cost-effective pathology solutions.
- The company focuses on AI-driven diagnostic tools for accurate disease diagnosis.
- PathAI's partnerships enhance its AI capabilities in precision medicine and drug development.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Competitive medical, dental, and vision insurance
Retirement plan options
Paid parental leave
Health & wellness benefits
Flexible work options
Generous paid time off
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 4%2 year growth
↑ 5%What You Should Know:– PathAI, a provider of AI-powered pathology solutions, today announced the launch of PathAssist Derm, an innovative tool designed to streamline the analysis of skin lesions.– Available now on the AISight® Image Management System (IMS), this research tool automates specimen orientation and identification, enabling pathologists to review samples more efficiently and accurately.PathAssist Derm CapabilitiesPathAssist Derm is the latest addition to PathAI’s suite of AI-powered solutions available on the AISight® IMS. This comprehensive platform provides pathologists with a range of tools to streamline their workflows and improve diagnostic accuracy. PathAssist Derm offers several key capabilities:Automated Specimen Orientation: Eliminates the need for manual orientation of glass slides, saving pathologists valuable time and reducing the risk of errors.Eliminates the need for manual orientation of glass slides, saving pathologists valuable time and reducing the risk of errors. Lesion Identification: Predicts the presence of 17 different skin lesion entities, including common and rare conditions, aiding in diagnosis and research.Predicts the presence of 17 different skin lesion entities, including common and rare conditions, aiding in diagnosis and research. Detailed Measurements: Provides precise measurements of lesion size and characteristics, facilitating quantitative analysis.“Skin cancer remains the most prevalent cancer worldwide, with over 1.5 million new cases diagnosed annually, which are associated with 60,000 deaths from melanoma alone,” said Andrew Beck, Co-Founder & CEO of PathAI. “These statistics present a critical opportunity for innovation in skin cancer research, both in the diagnostic and therapeutic realms
What You Should Know:– PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development.– This collaboration marks a milestone as the first at-scale deployment of AI technologies into a leading commercial biobank.Transforming Pathology Workflow: PathAI and Discovery Life Sciences Partner to Advance Precision MedicinePathAI and Discovery Life Sciences have entered a strategic partnership to integrate PathAI’s AISight® Image Management System (IMS), ArtifactDetect, and TumorDetect products into Discovery’s global biospecimens business. This collaboration aims to revolutionize traditional pathology workflows by automating routine tasks, enabling pathologists to dedicate more time to complex analyses, and empowering Discovery’s customers with enhanced tissue-level quantitative insights.Key Highlights of the Partnership:Automation of Pathology Workflows: PathAI’s advanced AI-driven tools will significantly reduce manual workload, saving time and increasing efficiency.PathAI’s advanced AI-driven tools will significantly reduce manual workload, saving time and increasing efficiency. Enhanced Data Quality: Discovery will provide customers with standardized, structured data and deeper tissue-level insights, improving the quality of research outputs.Discovery will provide customers with standardized, structured data and deeper tissue-level insights, improving the quality of research outputs. Custom AI-Driven Solutions: The partnership includes the development of a proprietary AI-driven tissue analysis panel exclusive to Discovery, advancing translational research and biomarker discovery for biopharma partners.Expanding AI-Driven InnovationsThis partnership extends beyond Discovery’s biospecimens business to include potential applications within Discovery’s Specialty Lab Services. These AI-driven solutions are expected to accelerate drug development and precision medicine by providing advanced insights for biopharma research initiatives.Advancing Precision Medicine and DiagnosticsWith increasing investments in immuno-oncology and antibody-drug conjugates, the demand for precise diagnostic tools that optimize patient selection continues to grow. By combining PathAI’s cutting-edge technology with Discovery’s structured, multi-modal datasets, the partnership aims to:Accelerate the development of new assays and diagnostic tools.Enhance the reliability and speed of biomarker discovery.Improve patient outcomes through advanced diagnostic precision.Leadership Perspective“Our digital pathology solutions will enable Discovery Life Sciences to provide unparalleled accuracy and speed in pathology assessments, ultimately benefiting their customers with enhanced data quality and insights,” said Andy Beck, CEO of PathAI
If 2023 was the year that generative AI came crashing into the world of humans and made everybody fear for their jobs and their futures, 2024 was the year that the narrative changed.The past 12 months have seen astonishing developments in healthcare and while those not engaging with AI will surely lose their jobs, for those who can afford it, AI is going to prolong lives and banish diseases that today damage people’s quality of life.I give it about five years. Hang on until then and while we may not live forever, we will live better and stronger, holding hands with the machines of loving grace.AI is pulsing through diseases like some kind of digital defibrillator. But is AI the angel on our shoulder or the devil in disguise? Will it be Jekyll or Hyde, what has 2025 in store for our health and our outlook on life?AI has already changed healthcare foreverDeepMind’s AlphaFold, the molecular mastermind that cracked protein structures has already turbocharged drug discovery. The result? Incipient therapies for living nightmares such as Alzheimer’s, cancer and rare genetic diseases. What used to take years now takes days to diagnose.AI is already used widely in healthcare. Algorithms are used to predict patients' risk of death or deterioration, to suggest diagnoses or triage patients, to record and summarise visits to save doctors work and to approve insurance claims.The thing about AI in diagnostics is that it doesn’t blink
This collaboration combines Deep Bio's clinically validated AI technology with PathAI's advanced digital pathology platform, expanding access to powerful diagnostic tools for prostate cancer.
PHILADELPHIA - October 10, 2024 - Clario, a leading provider of endpoint data solutions to the clinical trials industry, is excited to announce a strategic partnership with PathAI, a leader in AI-powered digital pathology solutions aimed at improving diagnostic accuracy and efficiency.